Intravenous Immunoglobulin (IVIG) Market Size Worth USD 24.76 Billion in 2032 | Emergen Research

The global Intravenous Immunoglobulin (IVIG) market size was USD 12.10 Billion in 2022 and is expected to register a revenue CAGR of 7.5% during the forecast period. The global intravenous immunoglobulin market is witnessing robust growth, driven by several key factors such as the increasing prevalence of immunodeficiency diseases, rising adoption of Intravenous Immunoglobulin (IVIG) treatment, and rapid technological advancements in therapy.

Click To get SAMPLE PDF (Including Full TOC, Graphs & Charts, Table & Figures)@ https://www.emergenresearch.com/request-sample/2728

Key Market Drivers

1. Growing Investment in Healthcare Industry: The healthcare sector's increasing investment is a significant contributor to market growth. With a focus on treating and preventing various immune disorders, the market has experienced rapid expansion.

2. Increasing Prevalence of Immunodeficiency Disorders: The rise in immunodeficiency diseases, including primary and secondary types, is a primary driver of market revenue growth. Factors such as the prevalence of HIV/AIDS and the aging population contribute to this trend.

3. Technological Advancements Enabling Personalized Treatments: Rapid technological advancements are leading to the development of innovative therapies, including nanoparticle-based IVIG and genetically engineered IVIG. These advancements enhance treatment efficacy and contribute to market growth.

4. Product Launches Driving Market Growth: Leading companies are launching new products, such as Biotest Ag's Yimmugo, to address the growing demand for IVIG therapies. These launches demonstrate a commitment to innovation and patient care.

Market Restraints

1. High Cost of Therapy: Despite increasing demand, the high cost of IVIG therapy remains a significant challenge, particularly in low- and middle-income countries. Limited reimbursement policies further restrict market growth.

Get a Discount On The Purchase Of This Report @ https://www.emergenresearch.com/request-discount/2728

Segment Insights

1. Intravenous Immunoglobulin (IVIG) Type Insights: The IgG type segment dominates the market, driven by its efficacy in treating autoimmune and inflammatory diseases. Steady growth is observed in the IgA segment due to increasing awareness and product approvals.

2. Intravenous Immunoglobulin Route of Administration Insights: The intravenous segment holds the largest market share, offering high bioavailability and efficacy in treating severe conditions. The subcutaneous segment is expected to grow steadily, driven by advancements in drug delivery technologies.

3. Intravenous Immunoglobulin Application Insights: Primary immunodeficiency disease accounts for the largest market share, followed by applications such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Product approvals and technological advancements contribute to segment growth.

4. Intravenous Immunoglobulin End-Use Insights: Hospitals dominate the market as the primary point of care for patients with immunodeficiency diseases. The comprehensive approach offered by hospitals ensures safe and effective IVIG therapy.

Interested in knowing more relevant information? Click here: https://www.emergenresearch.com/industry-report/intravenous-immunoglobulin-market

Intravenous Immunoglobulin (IVIG) Top Companies and Competitive Landscape

The global intravenous immunoglobulin market is fairly fragmented, with many large and medium-sized players accounting for the majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective intravenous immunoglobulin market.

Some major players included in the global intravenous immunoglobulin market report are:

• Baxter
• Pfizer Inc.
• Johnson and Johnson Private limited
• Takeda Pharmaceutical company Limited
• Grifols,S.A
• CSL
• Biotest AG
• Octapharma
• Bio Products Laboratory Limited
• LFB
Intravenous Immunoglobulin (IVIG) Latest Industry News

• On 18 April 2023, CSL Behring announced approval of S. Food and Drug Administration (FDA) approved prefilled syringe for Hizentra. The prefilled syringes are for individuals living with living with Primary Immunodeficiency (PI) or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). This Immune Globulin (Ig) is available in a simple, convenient and ready-to-use prefilled syringe. This announcement reinforces CSL Behring commitment to providing patients by eliminating the need for hospital-administered infusion with their new prefilled syringes. and treatment in the field of immunodeficiency disease.

Intravenous Immunoglobulin (IVIG) Market Segment Analysis

For the purpose of this report, Emergen Research has segmented the global intravenous immunoglobulin market on the basis of type, application, route of administration, end-use, and region:

• Type Outlook (Revenue, USD Billion; 2019-2032)
o IgA
o IgM
o IgD
o IgE
o IgG
• Route of administration (Revenue, USD Billion; 2019-2032)
o Intravenous
o Subcutaneous
• Application Outlook (Revenue, USD Billion; 2019-2032)
o Primary Immunodeficiency Diseases
o Myasthenia Gravis
o Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
o Hypogammaglobulinemia
o Multifocal motor neuropathy
o Kawasaki Disease
o Guillain-barre Syndrome
o Others
• End-Use Outlook (Revenue, USD Billion; 2019-2032)
o Hospitals
o Clinics
o Homecare
• Regional Outlook (Revenue, USD Billion; 2019-2032)
o North America
1. U.S.
2. Canada
3. Mexico
o Europe
1. Germany
2. France
3. U.K.
4. Italy
5. Spain
6. Benelux
7. Rest of Europe
o Asia Pacific
1. China
2. India
3. Japan
4. South Korea
5. Rest of APAC
o Latin America
1. Brazil
2. Rest of LATAM
o Middle East & Africa
1. Saudi Arabia
2. UAE
3. South Africa
4. Turkey
5. Rest of MEA

Look Over transcripts provided by Emergen Research

industrial packaging market
https://prtimes.jp/main/html/rd/p/000000152.000082259.html
green construction market
https://prtimes.jp/main/html/rd/p/000000151.000082259.html
automotive cybersecurity market
https://prtimes.jp/main/html/rd/p/000000150.000082259.html
automotive data monetization market
https://prtimes.jp/main/html/rd/p/000000148.000082259.html

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.